8-K: Armata Pharma Launches $100M At-The-Market Offering

Armata Pharmaceuticals, Inc. has entered into a Capital on Demand Sales Agreement to offer and sell up to $100 million of its common stock through an at-the-market offering program.

Summary

• Armata Pharmaceuticals, Inc. (the Company) has established an at-the-market (ATM) equity offering program with JonesTrading Institutional Services LLC.
• The Company may offer and sell, from time to time at its sole discretion, shares of its common stock with an aggregate offering price of up to $100,000,000.
• Sales will be made through JonesTrading as a sales agent, utilizing methods permitted for at-the-market offerings, including on the NYSE American or other trading markets.
• JonesTrading will receive a commission of up to 3.0% of the gross sales proceeds from any Placement Shares sold.
• The Company is not obligated to sell, and JonesTrading is not obligated to buy or sell, any shares under the Sales Agreement.
• The offering is being conducted pursuant to the Company's effective registration statement on Form S-3 (File No. 333-289585) and a prospectus supplement dated December 1, 2025.
• The actual amount that can be sold under this program is limited by SEC rules (General Instruction I.B.6 of Form S-3) to one-third of the Company's non-affiliate public float, which was $82,099,391 as of November 19, 2025, equating to approximately $27.3 million.

Sentiment

Score: 6

Explanation: The establishment of an ATM program is a neutral to slightly positive development as it provides a flexible funding mechanism. However, the significant potential for dilution and the actual limitation on the amount that can be raised (due to S-3 rules) temper the overall positive sentiment. It addresses a need for capital but also highlights ongoing funding requirements.

Positives

• Provides the Company with a flexible and efficient mechanism to raise capital as needed, without the significant upfront costs and market timing risks of traditional underwritten offerings.
• Allows for opportunistic capital raises based on market conditions and the Company's funding requirements, supporting ongoing research, clinical trials, and general operations.
• The 'at-the-market' structure offers discretion to management regarding the timing and volume of share sales.

Negatives

• Potential for dilution of existing shareholders as new shares are issued into the market.
• The 3.0% commission payable to JonesTrading represents a cost of capital for the Company.
• Uncertainty regarding the timing and pricing of future share sales, which could create downward pressure on the stock price.
• The stated maximum offering of $100,000,000 is significantly limited by SEC rules (General Instruction I.B.6 of Form S-3) to approximately $27.3 million, based on the Company's current public float.

Risks

• The Company is not obligated to sell, and JonesTrading is not obligated to buy or sell, any Placement Shares, meaning there is no guarantee of capital being raised.
• Sales of Placement Shares could cause dilution to existing shareholders, impacting their ownership percentage and potentially earnings per share.
• The market price of the common stock could be negatively affected by the perception or actual sales of shares under the ATM program.
• The Company's ability to raise capital is subject to prevailing market conditions and the trading price of its common stock.
• The aggregate market value of Placement Shares that can be sold is limited to one-third of the Company's non-affiliate public float (approximately $27.3 million), as per General Instruction I.B.6 of Form S-3, despite the $100 million program size.

Future Outlook

The Company intends to use the net proceeds from any sales of common stock as described in the 'Use of Proceeds' section of its prospectus. This typically includes general corporate purposes, working capital, and potentially funding research and development or other strategic initiatives. The ATM program provides a flexible mechanism for the Company to address future capital needs.

Management Comments

• Armata Pharmaceuticals, Inc. entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC for an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $100,000,000.
• The Company is not obligated to sell, and JonesTrading is not obligated to buy or sell, any Placement Shares under the Sales Agreement.

Industry Context

At-the-market offerings are a common capital-raising tool for biotechnology and pharmaceutical companies, particularly those in clinical development stages. This mechanism provides flexible access to capital without the significant upfront costs and market timing risks of traditional underwritten offerings. It allows companies like Armata, which are often pre-revenue or have limited revenue, to fund ongoing research, clinical trials, and general operations as needed, potentially minimizing immediate dilution pressure compared to a large single offering.

Comparison to Industry Standards

• The 3.0% commission rate for the sales agent is within the typical range for ATM offerings in the biotechnology sector, which commonly falls between 2% and 3.5%.
• The maximum offering size of $100 million is substantial for a company with a public float of approximately $82 million, but the actual amount that can be sold is limited by SEC rules (General Instruction I.B.6 of Form S-3) to one-third of the public float, which is approximately $27.3 million. This is a standard limitation for smaller reporting companies utilizing Form S-3 for primary offerings.
• The structure of the agreement, allowing sales 'from time to time at its sole discretion,' is standard for ATM programs, providing flexibility that is highly valued by development-stage companies.

Stakeholder Impact

• Shareholders: Potential for dilution as new shares are issued, which could impact earnings per share and ownership percentage.
• Company (Management/Operations): Provides a flexible source of capital to fund ongoing operations, research and development, and strategic initiatives, reducing immediate financing pressure.
• Creditors: A stronger cash position from capital raises could improve the Company's financial stability and ability to meet obligations.

Next Steps

• The Company may, at its discretion, issue placement notices to JonesTrading to sell shares of common stock.
• JonesTrading will use commercially reasonable efforts to sell Placement Shares according to the terms of any placement notice.
• The Company will continue to comply with SEC filing requirements and maintain its listing on the NYSE American.

Key Dates

Recommendation

The establishment of an ATM offering provides a necessary and flexible capital-raising tool for Armata Pharmaceuticals, which is common for development-stage biotech companies. While it addresses potential funding needs, the program also introduces the risk of dilution for existing shareholders and the actual amount that can be raised is significantly less than the stated maximum due to regulatory limitations (approximately $27.3 million out of $100 million). This suggests ongoing capital requirements and potential future dilution, but also a pathway to secure funding. Given these factors, a 'hold' recommendation is appropriate, as the offering itself is a standard operational move rather than a significant positive or negative catalyst, but the underlying need for capital and potential dilution warrant caution.

Keywords

Armata Pharmaceuticals, ARMP, At-The-Market Offering, ATM, Equity Offering, Capital Raise, Common Stock, Dilution, SEC Filing, Form 8-K, JonesTrading, Public Float, S-3 Filing, Biotechnology, Pharmaceuticals